Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:SRPT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT) , triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit ...

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after the Nasdaq Global Market closes on Wednesday, August ...

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration notified Sarepta that it may lift its voluntary ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Sarepta Therapeutics (SRPT) reports results for the quarter ended June 2025. While this widely-known consensus ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the September 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Shares of Sarepta Therapeutics SRPT are declining in the pre-market hours today after the announcement that it will voluntarily and temporarily halt all U.S. shipments of Elevidys, effective at ...

Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the September 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...